ConductScience.org, home

Paper316744

Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Evans WE and 4 others. Cancer Chemother Pharmacol, 1979. Cited by 113 papers, by iCite.

Cite this record

ConductScience Library. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Papers, record 316744. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/316744

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1979
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
113
iCite
Relative citation ratio, by iCite
4.82
iCite
Revised in PubMed
2022-04-09
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Evans WEW E
2Pratt CBC B
3Taylor RHR H
4Barker LFL F
5Crom WRW R

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MethotrexateMajor topic
Bone Neoplasms
Drug Therapy, Combination
Half-Life
Humans
Kinetics
Leucovorin
Osteosarcoma
Risk
Time Factors

Source PubMed

Download CSV of topics

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1832268The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.Cancer Res1977https://conductscience.org/library/papers/832268PubMed
2304763High-dose methotrexate, not a conventional treatment.Cancer Treat Rep1978https://conductscience.org/library/papers/304763PubMed
35573769Methotrexate tissue distribution: prediction by a mathematical model.J Natl Cancer Inst1971https://conductscience.org/library/papers/5573769PubMed
4884693Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity.Cancer Treat Rep1977https://conductscience.org/library/papers/884693PubMed
5301662"Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment.Semin Oncol1977https://conductscience.org/library/papers/301662PubMed
6301783Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.Cancer Treat Rep1977https://conductscience.org/library/papers/301783PubMed
71175171Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man.Cancer Chemother Rep1975https://conductscience.org/library/papers/1175171PubMed
8306284Serum distribution of citrovorum factor and 5-methyltetrahydrofolate following oral and im administration of calcium leucovorin in normal adults.Cancer Treat Rep1978https://conductscience.org/library/papers/306284PubMed
9305823"Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.Cancer Treat Rep1978https://conductscience.org/library/papers/305823PubMed
105127083Methotrexate pharmacokinetics.J Pharm Sci1971https://conductscience.org/library/papers/5127083PubMed
11304376Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue.Cancer Treat Rep1977https://conductscience.org/library/papers/304376PubMed
12304375Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.Cancer Res1978https://conductscience.org/library/papers/304375PubMed
134547680Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors.Cancer Res1974https://conductscience.org/library/papers/4547680PubMed
1419151Recovery from toxicity associated with high-dose methotrexate: prognostic factors.Cancer Treat Rep1977https://conductscience.org/library/papers/19151PubMed
151086423High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity.Med Pediatr Oncol1976https://conductscience.org/library/papers/1086423PubMed
165073303Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern.Eur J Cancer (1965)1972https://conductscience.org/library/papers/5073303PubMed
174536622Effective absorption and utilization of oral formyltetrahydrofolate in man.N Engl J Med1972https://conductscience.org/library/papers/4536622PubMed
184843162Relative toxicity of methotrexate in several tissues of mice bearing Lewis lung carcinoma.J Pharmacol Exp Ther1974https://conductscience.org/library/papers/4843162PubMed
191087180The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides.Cancer Res1976https://conductscience.org/library/papers/1087180PubMed
20618710Effect of pleural effusion on high-dose methotrexate kinetics.Clin Pharmacol Ther1978https://conductscience.org/library/papers/618710PubMed

See all 24 referencesDownload CSV of references

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 113 citations.

PMIDTitleJournalYearIn PapersSource
42323774Toxicity-Tailored Thresholds of Delayed Methotrexate Elimination in Non-Hodgkin Lymphoma: A Population-Based Approach to Therapy Optimization.Eur J Drug Metab Pharmacokinet2026https://conductscience.org/library/papers/42323774PubMed
42312165A Minimally Invasive, Subcutaneous Biosensor Reliably Estimates Plasma Methotrexate Exposure and Quantifies Plasma-to-Tissue Transport Kinetics.ACS Pharmacol Transl Sci2026https://conductscience.org/library/papers/42312165PubMed
42243443A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study.Clin Pharmacokinet2026https://conductscience.org/library/papers/42243443PubMed
39640903Accidental methotrexate overdose leading to multisystem toxicity: A case report.Toxicol Rep2024https://conductscience.org/library/papers/39640903PubMed
38026729Low serum level and chronic toxicity for methotrexate. Case Report.Qatar Med J2023https://conductscience.org/library/papers/38026729PubMed
34147089Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients.BMC Cancer2021https://conductscience.org/library/papers/34147089PubMed
33655525Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.Pharmacotherapy2021https://conductscience.org/library/papers/33655525PubMed
32535662High-dose methotrexate in ICU patients: a retrospective study.Ann Intensive Care2020https://conductscience.org/library/papers/32535662PubMed
32090349Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma.Pharmacotherapy2020https://conductscience.org/library/papers/32090349PubMed
31657864Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours.Br J Clin Pharmacol2020https://conductscience.org/library/papers/31657864PubMed
31308758Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia.Cancer Manag Res2019https://conductscience.org/library/papers/31308758PubMed
27496039Preventing and Managing Toxicities of High-Dose Methotrexate.Oncologist2016https://conductscience.org/library/papers/27496039PubMed
27104192Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma.Blood Res2016https://conductscience.org/library/papers/27104192PubMed
24859553The utility of online haemodiafiltration in methotrexate poisoning.BMJ Case Rep2014https://conductscience.org/library/papers/24859553PubMed
23760811Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.Cancer Chemother Pharmacol2013https://conductscience.org/library/papers/23760811PubMed
21192315Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer.Ther Drug Monit2011https://conductscience.org/library/papers/21192315PubMed
17115148Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.Eur J Clin Pharmacol2007https://conductscience.org/library/papers/17115148PubMed
12403645Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.Clin Pharmacokinet2002https://conductscience.org/library/papers/12403645PubMed
10803455Adaptive control methods for the dose individualisation of anticancer agents.Clin Pharmacokinet2000https://conductscience.org/library/papers/10803455PubMed
8306417Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8306417PubMed

See all 30 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/316744

GET https://conductscience.org/api/papers/v1/316744/references?page=2